Stevanato Group S.p.A.

5 days ago · seekingalpha.com

Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

13 days ago · businesswire.com

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Confere.

20 days ago · gurufocus.com

On September 01, 2026, Stevanato Group SpA (STVN) shares fell 3.4% to a current price of $20.71, trading within a 52-week range of $12.89 to $28.00. This recent

24 days ago · gurufocus.com

On August 28, 2026, Stevanato Group SpA (STVN) shares fell 5.7%, closing at $21.03. The stock has experienced a volatile year, with a 52-week range of $12.89 to

2 months ago · zacks.com

Stevanato (STVN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

2 months ago · seekingalpha.com

Stevanato Group S.p.A. (STVN) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Stevanato Group (STVN) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.

2 months ago · businesswire.com

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increase.

2 months ago · businesswire.com

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group's proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Mark.

2 months ago · businesswire.com

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discu.